A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia

Diabetic Medicine

Volumn 33, Issue 4, 2016, Pages 478-487

  Heller, S ^a   Mathieu, C ^b   Kapur, R ^c   Wolden, M L ^c   Zinman, B ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c NOVO NORDISK A S   (Denmark)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN DEGLUDEC; INSULIN GLARGINE; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ARTICLE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAINTENANCE THERAPY; META ANALYSIS; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; CIRCADIAN RHYTHM; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RISK;

CIRCADIAN RHYTHM; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; PRACTICE GUIDELINES AS TOPIC; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK;

EID: 84961158501     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13002     Document Type: Article

References (22)

1. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012; 14: 944-950.
2. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
3. Garber AJ, King AB, Del Prato S, Sreenan S, Balchi MK, Muñoz-Torres M et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
4. ™ LOW VOLUME trial. Diabetes Care 2013; 36: 2536-2542.
5. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
6. Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M et al. on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care 2013; 364: 858-864.
7. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Invest 2013; 4: 605-612.
8. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T et al. on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35: 2464-2471.
9. ®: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162.
10. Ratner R, Gough S, Mathieu C, Del Prato S, Bode B, Mersebach H et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184.
11. Brod M, Christensen T, Thomsen T, Bushnell D. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011; 14: 665-671.
12. Brod M, Wolden M, Pohlman B, Christensen T. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013; 15: 546-557.
13. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008; 24: 353-363.
14. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. 20 January 2010. CPMP/EWP/1080/00 Rev. 1.
15. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L et al. Hypoglycaemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-1395.
16. Hollander P, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M.et al. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with less hypoglycaemia in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab 2015; 17: 202-206.
17. Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013; 30: 1293-1297.
18. Rodbard HW, Cariou B, Zinman B, Handlesman Y, Philis-Tsimikas A, Skjøth TV et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med 2013; 30: 1298-1304.
19. Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015; 18: 56-68.
20. Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes Obes Metab 2014; 16: 366-375.
21. Landstedt-Hallin L. Changes in HbA1c, insulin dose and incidence of hypoglycaemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin 2015; 31: 1487-1493.
22. Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice - a case-based evaluation. J Med Econ 2015; 18: 96-105.